Market research
PH7.F PYC Therapeutics Limited
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 296M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.25
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 296M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.25
About
About PYC Therapeutics Limited
PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PH7.F discussion.
5 years, 4 months ago
PYC Therapeutics Limited is currently in a long term downtrend where the price is trading 4.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
PYC Therapeutics Limited's total revenue sank by 0.0% to $29K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 239.1% to $-3M since the same quarter in the previous year.
Based on the above factors, PYC Therapeutics Limited gets an overall score of 1/5.